WashU early AD initiative could yield broader clues
By Randy Osborne · January 19, 2017
485704918
If intervening ahead of symptoms in Alzheimer’s disease (AD) works in people with gene mutations that predispose them to getting sick at a younger age, then it will probably work in the rest of the population, principal investigator Randall Bateman theorized to BioWorld Today, and his team at Washington University (WashU) – testing drugs provided by big pharma – hopes to prove as much.
Categories: Uncategorized